Targeting cancer with power and precision


Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) is a late-stage, clinical oncology company advancing novel product candidates based upon the Company’s targeted protein therapeutics (TPTs) platform. TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. Eleven’s lead TPT, Vicinium™, is currently in a Phase 3 trial in non-muscle invasive bladder cancer, with topline three-month data expected in mid-2018. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistant mechanisms. Additionally, the Company believes that its TPT’s cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors.


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.elevenbio.com

Recent News

January 2, 2018
Eleven Biotherapeutics to Present at Biotech Showcase 2018

December 13, 2017
Eleven Biotherapeutics Announces Chief Scientific Officer To Chair A Session At The Antibody Engineering And Therapeutics Meeting

November 30, 2017
Eleven Biotherapeutics to Present at the LD Micro Main Event 2017

Read More News

Associated Team Members

Mark Levin
Partner

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner